Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

1.

Low bone mass in Pompe disease: muscular strength as a predictor of bone mineral density.

van den Berg LE, Zandbergen AA, van Capelle CI, de Vries JM, Hop WC, van den Hout JM, Reuser AJ, Zillikens MC, van der Ploeg AT.

Bone. 2010 Sep;47(3):643-9. doi: 10.1016/j.bone.2010.06.021. Epub 2010 Jun 25.

PMID:
20601298
[PubMed - indexed for MEDLINE]
2.

Bone mineral density in adult patients with Pompe disease.

Papadimas GK, Terzis G, Spengos K, Methenitis S, Papadopoulos C, Vassilopoulou S, Manta P.

Bone. 2011 Feb;48(2):417; author reply 418-9. doi: 10.1016/j.bone.2010.09.030. Epub 2010 Sep 25. No abstract available.

PMID:
20884384
[PubMed - indexed for MEDLINE]
3.

Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk.

Van den Hout JM, Kamphoven JH, Winkel LP, Arts WF, De Klerk JB, Loonen MC, Vulto AG, Cromme-Dijkhuis A, Weisglas-Kuperus N, Hop W, Van Hirtum H, Van Diggelen OP, Boer M, Kroos MA, Van Doorn PA, Van der Voort E, Sibbles B, Van Corven EJ, Brakenhoff JP, Van Hove J, Smeitink JA, de Jong G, Reuser AJ, Van der Ploeg AT.

Pediatrics. 2004 May;113(5):e448-57.

PMID:
15121988
[PubMed - indexed for MEDLINE]
4.

Body composition analysis in late-onset Pompe disease.

Papadimas GK, Terzis G, Methenitis S, Spengos K, Papadopoulos C, Vassilopoulou S, Kavouras S, Michelakakis H, Manta P.

Mol Genet Metab. 2011 Jan;102(1):41-3. doi: 10.1016/j.ymgme.2010.09.002. Epub 2010 Sep 16.

PMID:
20926325
[PubMed - indexed for MEDLINE]
5.

24-months results in two adults with Pompe disease on enzyme replacement therapy.

Vielhaber S, Brejova A, Debska-Vielhaber G, Kaufmann J, Feistner H, Schoenfeld MA, Awiszus F.

Clin Neurol Neurosurg. 2011 Jun;113(5):350-7. doi: 10.1016/j.clineuro.2010.09.016. Epub 2011 Apr 7.

PMID:
21477922
[PubMed - indexed for MEDLINE]
6.

Adult Pompe disease: clinical manifestations and outcome of the first Greek patients receiving enzyme replacement therapy.

Papadimas GK, Spengos K, Konstantinopoulou A, Vassilopoulou S, Vontzalidis A, Papadopoulos C, Michelakakis H, Manta P.

Clin Neurol Neurosurg. 2011 May;113(4):303-7. doi: 10.1016/j.clineuro.2010.12.005. Epub 2011 Jan 7.

PMID:
21216089
[PubMed - indexed for MEDLINE]
7.

Recombinant human acid alpha-glucosidase (rhGAA) in adult patients with severe respiratory failure due to Pompe disease.

Orlikowski D, Pellegrini N, Prigent H, LaforĂȘt P, Carlier R, Carlier P, Eymard B, Lofaso F, Annane D.

Neuromuscul Disord. 2011 Jul;21(7):477-82. doi: 10.1016/j.nmd.2011.04.001. Epub 2011 May 6.

PMID:
21550241
[PubMed - indexed for MEDLINE]
8.

Acid alpha-glucosidase deficiency (glycogenosis type II, Pompe disease).

Raben N, Plotz P, Byrne BJ.

Curr Mol Med. 2002 Mar;2(2):145-66. Review.

PMID:
11949932
[PubMed - indexed for MEDLINE]
9.

Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease.

Thurberg BL, Lynch Maloney C, Vaccaro C, Afonso K, Tsai AC, Bossen E, Kishnani PS, O'Callaghan M.

Lab Invest. 2006 Dec;86(12):1208-20. Epub 2006 Oct 30.

PMID:
17075580
[PubMed - indexed for MEDLINE]
Free Article
10.

Enzyme replacement therapy in severe adult-onset glycogen storage disease type II.

Ravaglia S, Danesino C, Pichiecchio A, Repetto A, Poloni GU, Rossi M, Fratino P, Moglia A, Costa A.

Adv Ther. 2008 Aug;25(8):820-9. doi: 10.1007/s12325-008-0086-y.

PMID:
18704279
[PubMed - indexed for MEDLINE]
11.

Pompe disease (glycogen storage disease type II): clinical features and enzyme replacement therapy.

van der Beek NA, Hagemans ML, van der Ploeg AT, Reuser AJ, van Doorn PA.

Acta Neurol Belg. 2006 Jun;106(2):82-6. Review.

PMID:
16898258
[PubMed - indexed for MEDLINE]
12.

Juvenile acid maltase deficiency presenting as paravertebral pseudotumour.

Iancu TC, Lerner A, Shiloh H, Bashan N, Moses S.

Eur J Pediatr. 1988 May;147(4):372-6.

PMID:
3135192
[PubMed - indexed for MEDLINE]
13.

Acid alpha-glucosidase deficiency (Pompe disease).

Fukuda T, Roberts A, Plotz PH, Raben N.

Curr Neurol Neurosci Rep. 2007 Jan;7(1):71-7. Review.

PMID:
17217857
[PubMed - indexed for MEDLINE]
14.

Enzyme therapy for pompe disease with recombinant human alpha-glucosidase from rabbit milk.

Van den Hout JM, Reuser AJ, de Klerk JB, Arts WF, Smeitink JA, Van der Ploeg AT.

J Inherit Metab Dis. 2001 Apr;24(2):266-74.

PMID:
11405345
[PubMed - indexed for MEDLINE]
15.

Screening for Pompe disease using a rapid dried blood spot method: experience of a clinical diagnostic laboratory.

Goldstein JL, Young SP, Changela M, Dickerson GH, Zhang H, Dai J, Peterson D, Millington DS, Kishnani PS, Bali DS.

Muscle Nerve. 2009 Jul;40(1):32-6. doi: 10.1002/mus.21376.

PMID:
19533645
[PubMed - indexed for MEDLINE]
16.

Morphological changes in muscle tissue of patients with infantile Pompe's disease receiving enzyme replacement therapy.

Winkel LP, Kamphoven JH, van den Hout HJ, Severijnen LA, van Doorn PA, Reuser AJ, van der Ploeg AT.

Muscle Nerve. 2003 Jun;27(6):743-51.

PMID:
12766987
[PubMed - indexed for MEDLINE]
17.

Effect of aerobic and resistance exercise training on late-onset Pompe disease patients receiving enzyme replacement therapy.

Terzis G, Dimopoulos F, Papadimas GK, Papadopoulos C, Spengos K, Fatouros I, Kavouras SA, Manta P.

Mol Genet Metab. 2011 Nov;104(3):279-83. doi: 10.1016/j.ymgme.2011.05.013. Epub 2011 May 19.

PMID:
21640624
[PubMed - indexed for MEDLINE]
18.

Demonstration of acid alpha-glucosidase in different types of Pompe disease by use of an immunochemical method.

Ninomiya N, Matsuda I, Matsuoka T, Iwamasa T, Nonaka I.

J Neurol Sci. 1984 Nov-Dec;66(2-3):129-39.

PMID:
6442343
[PubMed - indexed for MEDLINE]
19.

Murine muscle cell models for Pompe disease and their use in studying therapeutic approaches.

Takikita S, Myerowitz R, Zaal K, Raben N, Plotz PH.

Mol Genet Metab. 2009 Apr;96(4):208-17. doi: 10.1016/j.ymgme.2008.12.012. Epub 2009 Jan 22.

PMID:
19167256
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Rate of progression and predictive factors for pulmonary outcome in children and adults with Pompe disease.

van der Beek NA, van Capelle CI, van der Velden-van Etten KI, Hop WC, van den Berg B, Reuser AJ, van Doorn PA, van der Ploeg AT, Stam H.

Mol Genet Metab. 2011 Sep-Oct;104(1-2):129-36. doi: 10.1016/j.ymgme.2011.06.012. Epub 2011 Jun 24.

PMID:
21763167
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk